+ Filter
Loading...
Custom Services order now ship next day

Anti-IRAK4 Recombinant Antibody Products

Loading...

Anti-IRAK4 Products

View More Products

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


Creative Biolabs is a trusted provider of high - quality anti - IRAK4 antibodies, essential for driving breakthroughs in biomedical research. Our commitment to precision and consistency is reflected in our stringent quality control protocols, ensuring each antibody delivers reliable and reproducible performance. We strive to equip researchers with dependable tools that fuel scientific progress.

IRAK4: A Key Signaling Kinase in Innate Immune Responses

IRAK4, or Interleukin-1 receptor-associated kinase 4, is a pivotal element in the TLR and IL-1R signaling cascades, playing a crucial part in triggering innate immune reactions. By facilitating the activation of downstream signals, it promotes the synthesis of inflammatory cytokines. Deviations in IRAK4 function have been linked to autoimmune diseases, persistent inflammation, and specific malignancies. Given its central position in immune modulation, IRAK4 represents an attractive target for therapeutic strategies, particularly in conditions such as rheumatoid arthritis, lupus, and B-cell cancers. Consequently, there is an increasing focus on creating IRAK4-targeted inhibitors and antibodies for both research endeavors and clinical treatments.

Alternative Names

IPD1; IMD67; REN64; IRAK-4; NY-REN-64

Background

This gene encodes a kinase that activates NF-kappaB in both the Toll-like receptor (TLR) and T-cell receptor (TCR) signaling pathways. The protein is essential for most innate immune responses. Mutations in this gene result in IRAK4 deficiency and recurrent invasive pneumococcal disease. Multiple transcript variants encoding different isoforms have been found for this gene.

Protein class

Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets

Predicted location

Intracellular

Single cell type specificity

Low cell type specificity

Immune cell specificity

Low immune cell specificity

Cell line specificity

Cell line enhanced (U-937)

Interaction

Associates with MYD88 and IRAK2 to form a ternary complex called the Myddosome (PubMed:16951688, PubMed:24316379). Once phosphorylated, IRAK4 dissociates from the receptor complex and then associates with the TNF receptor-associated factor 6 (TRAF6), IRAK1, and PELI1; this intermediate complex is required for subsequent NF-kappa-B activation (PubMed:11960013, PubMed:12496252, PubMed:16951688). Direct binding of SMAD6 to PELI1 prevents complex formation and hence negatively regulates IL1R-TLR signaling and eventually NF-kappa-B-mediated gene expression (PubMed:16951688). Interacts with IL1RL1 (PubMed:16286016). Interacts (when phosphorylated) with IRAK1 (PubMed:33238146). May interact (when phosphorylated) with IRAK3 (PubMed:33238146).

Molecular function

Kinase, Serine/threonine-protein kinase, Transferase

More Types Infomation

Anti-IRAK4 rAb Products

We specialize in providing high-quality anti-IRAK4 recombinant antibodies to support research in drug development. Committed to scientific progress, we offer reliable and effective products to enhance target-related studies. Our focus is on delivering dependable solutions that empower researchers in advancing their discoveries.

Cat. No. Product Name Target Species Host Species Applications
MOB-2079z Mouse Anti-IRAK4 Recombinant Antibody (clone 27A3) Human Mouse WB; ELISA; FC; IHC
TAB-451CL Anti-Human IRAK4 Recombinant Antibody Human Mouse ELISA
VS3-FY761 Recombinant Rabbit Anti-IRAK4 Antibody (clone R01-1B2) Human Rabbit WB; IHC; ICC; IF
MOB-0992CT Recombinant Mouse anti-Human IRAK4 Monoclonal antibody (A8A8) Human Mouse ELISA; IHC; WB

Creative Quality Control

We are committed to delivering antibody products of exceptional quality, carefully developed using cutting-edge technologies and stringent quality control standards. Through providing these premium antibodies, we aim to support scientific research and aid in the development of more effective IRAK4-targeted therapies.

WB analysis of VS3-FY761. (Creative Biolabs Original)Fig.1 WB analysis of anti-IRAK4 antibody
(Cat# VS3-FY761, Creative Biolabs).

IHC-P analysis of VS3-FY761. (Creative Biolabs Original)Fig.2 IHC-P analysis of anti-IRAK4 antibody
(Cat# VS3-FY761, Creative Biolabs).

Customer Reviews

Excellent
L**gh
Recombinant Rabbit Anti-IRAK4 Antibody (clone R01-1B2) (Cat#: VS3-FY761)
The Recombinant Rabbit Anti-IRAK4 Antibody is suitable for detecting IRAK4 in WB, IHC, ICC, and IF. It offers reliable and consistent performance, supporting research on immune signaling and inflammation. Its specificity makes it useful for studying IRAK4-related pathways in cells and tissues.
16/Feb/2024
Excellent
Ca**ce
Mouse Anti-IRAK4 Recombinant Antibody (clone 27A3) (Cat#: MOB-2079z)
The Mouse Anti-IRAK4 Recombinant Antibody is a versatile reagent for detecting IRAK4 in WB, ELISA, FC, and IHC. It provides consistent results and is useful for research on inflammation, immune signaling, and IRAK4-related diseases.
23/Oct/2023

rAb Production

With years of specialized experience in expression vector design, transfected cell line screening, and antibody purification, we offer a full range of services from gene synthesis to antibody production. We are committed to providing dependable, high-quality products designed to support the unique requirements of biomedical researchers. By emphasizing consistency and streamlined processes, we help scientists advance their work efficiently and effectively. Our focus on quality and reliability contributes to progress in both research and therapeutic innovation.

Featured Anti-IRAK4 Recombinant Antibody Production PlatformsMilligram-scale anti-IRAK4 recombinant antibody production. (Creative Biolabs Original)
Fig.3 Milligram-scale recombinant antibody production.

Gram-scale anti-IRAK4 recombinant antibody production. (Creative Biolabs Original)Fig.4 Gram-scale recombinant antibody production.

rAb Modalities

Our team focuses on offering a wide range of recombinant antibody formats to support various scientific applications, such as basic research and drug discovery. Our antibodies are meticulously designed to address the unique requirements of researchers, ensuring top-notch quality and dependability. By providing flexible solutions, we strive to foster scientific progress and aid in advancing biomedical research, empowering researchers to make impactful discoveries.

Full Length Anti-IRAK4 Recombinant Antibody Production and Modalities. (Creative Biolabs Original) Fig.5 Full Length Anti-IRAK4 Recombinant Antibody Production and Modalities.

Drug Information Targeting IRAK4

Table 1. Therapeutic approaches targeting IRAK4 in clinical development.

Research phase Company Classification Indications Details
Phase II Kymera Therapeutics Small Molecules Atopic dermatitis; Hidradenitis suppurativa It is an orally available IRAK4 degradation inducer, is in phase II clinical development for the treatment of hidradenitis suppurativa and atopic dermatitis.
Phase II Gilead Small Molecules Cutaneous lupus erythematosus; Inflammatory bowel disease It is an oral, small-molecule inhibitor of the IRAK-4 kinase in phase II clinical development as a treatment for cutaneous lupus erythematosus.
Phase II Bayer Small Molecules Atopic dermatitis; Endometriosis It is an oral, small-molecule IRAK-4 inhibitor in early clinical development for the treatment of immune-mediated inflammatory disorders.
Phase I/II Aurigene Small Molecules Acute myeloid leukemia; Cancer It is an orally available small molecule inhibitor of the interleukin-1 receptor-associated kinase 4 (IRAK4).
Phase I AstraZeneca Others Inflammatory disorders It is an orally available interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitor in early clinical development for the treatment of inflammatory disorders.
Phase I Rigel Others Myelodysplasia This is an oral dual inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), being developed in phase I studies for the treatment of patients with lower-risk myelodysplastic syndromes (MDS) who are refractory or resistant to prior therapies.
Phase I Eilean Therapeutics Others Acute myeloid leukemia It is an oral selective pan-FLT3/ IRAK4 inhibitor in phase I development for the treatment of FLT3 mutated acute myeloid leukemia (AML).

If you're interested in learning more about our anti-IRAK4 recombinant antibodies or have any inquiries, don't hesitate to reach out us. Our skilled team is dedicated to providing full support, offering expert advice and customized solutions to suit your research needs. We aim to provide a smooth experience, helping you achieve reliable and significant outcomes in your scientific endeavors. Your success is our priority, and we're here to assist you every step of the way.

Go to compare

Go to compare